Valneva, a French biotech firm, has launched an early- to midstage trial in the UK to evaluate VLA2001, its inactivated and adjuvanted COVID-19 vaccine. The trial will be done at four sites throughout the UK with the support of the National Institute for Health Research, and the company has partnered with the British government and has agreed to supply 60 million doses of its COVID-19 vaccine candidate to the UK by the second half of next year if vaccine development proves successful.